Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Tempest Therapeutics announced plans to advance TPST-4003, its lead in vivo CAR-T candidate, into an investigator-initiated clinical study for myasthenia gravis and multiple sclerosis in the fourth quarter of 2026. The trial is expected to enroll approximately 10 patients, with initial safety and pharmacodynamic data anticipated in the first half of 2027.
Key figures
- Trial enrollment
- approximately 10 patients
- First dosing date
- fourth quarter of 2026
- Initial data date
- first half of 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.